A vascular access model proven over a decade in Indianapolis, now launching where the need is sharpest — hospital systems in North Dakota and northern Minnesota.
We didn't start with a growth story — we started with eleven years of audited operations, multi-year hospital contracts, and a published quality record. Expansion is that same model, transplanted to markets where dedicated vascular access coverage is hardest to staff.
Smaller metros and regional health systems face the steepest recruiting challenges for specialized inserters, and the economics are unforgiving: 46% of rural hospitals operate at negative margins and 432 are vulnerable to closure (Chartis Center for Rural Health, 2025). A dedicated, vendor-supplied, per-procedure service is the only economically rational way for these facilities to get specialist-level vascular access — no FTE, no capital, no recruiting bet.
The full Indianapolis playbook: credentialed specialists, vendor-provided supply chain, imaging confirmation on every placement, per-procedure billing, and 24/7 coverage — with quality reporting from the first quarter.
Continuous hospital service in central Indiana since 2015. The proving ground for the model, and still growing.
Grand Forks and surrounding regional systems — communities where specialized vascular access coverage is scarce and travel-staffing economics don't pencil.
Duluth and the northern corridor — regional health systems balancing growing infusion demand against a tight clinical labor market.
When a regional facility can't place a line, the patient waits, gets repeated failed sticks, or gets transferred — and a transfer is lost revenue, transport cost, and a family driving hours. Keeping vascular access local keeps therapy, revenue, and patients where they belong.
The first facilities in each launch market shape the coverage model around their needs — coverage windows, ordering workflow, and reporting are built with the founding partners, not retrofitted. Early conversations get first priority in the launch sequence.
We're scheduling launch-market conversations now.
Get in early